Inventor · disambiguated record
Ulf Forssmann
Also filed as: FORSSMANN ULF · FORSSMANN ULF JOERG
3 granted patents·10 pending applications·4 citations·filing 2001–2022
59Inventor score
Files withGENMAB AS7ARMBRUSTER BIOTECHNOLOGY GMBH1ARMBRUSTER FRANZ PAUL1GENMAB BV1IPF PHARMACEUTICALS GMBH1
Top patents by PatentIndex Score
13 records- 0162US8808691B2Method for treating tumors and their metastasesARMBRUSTER FRANZ PAUL·Filed 2010·Granted Aug 19, 2014·1 cites·10 claims
- 0262US7741292B2Method of inhibiting the emigration of cells from the intravascular compartment into tissuesIPF PHARMACEUTICALS GMBH·Filed 2008·Granted Jun 22, 2010·1 cites·7 claims
- 0358US2024262924A1Combination dosage regime of cd137 and pd-l1 binding agentsGENMAB AS·Filed 2022·Application pending·0 cites
- 0456US2024109972A1Antibody and taxane combination therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 0554US7825219B2Medicament for treating tumours and their metastasesARMBRUSTER BIOTECHNOLOGY GMBH·Filed 2002·Granted Nov 2, 2010·2 cites·9 claims
- 0651US2023087164A1Antibodies for use in therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 0750US2021393793A1Axl-specific antibodies for treatment of non-small cell lung cancerGENMAB AS·Filed 2019·Application pending·0 cites
- 0848US2022315661A1Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancerGENMAB BV·Filed 2020·Application pending·0 cites
- 0947US2021070869A1Axl-specific antibodies for cancer treatmentGENMAB AS·Filed 2019·Application pending·0 cites
- 1047US2022273809A1Axl antibody-drug conjugates for use in treating cancerGENMAB AS·Filed 2020·Application pending·0 cites
- 1137US2019233522A1New dosage regimens for antibody drug conjugates based on anti-axl antibodiesGENMAB AS·Filed 2017·Application pending·0 cites
- 1235US2005142101A1Method of inhibiting the emigration of cells from the intravascular compartment into tissuesFiled 2003·Application pending·0 cites
- 1335US2003186889A1Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interactionFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →